Survodutide SYNCHRONIZE-2: the type 2 diabetes results
In 752 adults with obesity and type 2 diabetes, once-weekly survodutide lowered body weight by 8.2-9.8% at 76 weeks versus 3.9% on placebo. That is a real effect, but smaller than the 12-13% seen in SYNCHRONIZE-1 (people without diabetes). Here is the full read.
How It Works
Survodutide is an investigational glucagon receptor-GLP-1 receptor dual agonist given as a once-weekly injection. The NEJM authors describe it as having potential weight-reducing and metabolic benefits beyond GLP-1 receptor activity alone.
Double-blind, placebo-controlled phase 3 trial: adults with type 2 diabetes and a BMI of 27 or more were randomized 1:1:1 to survodutide (titrated up to 3.6 mg or 6.0 mg weekly) or placebo for 76 weeks, alongside diet and physical-activity recommendations. 133 sites in 19 countries.
Mean age 55.7 years, BMI 36.5, body weight 104.1 kg and HbA1c 7.4%; 50.7% were women. 69.0% had hypertension and 67.6% dyslipidaemia. 78.7% were taking metformin and 34.2% an SGLT2 inhibitor.
The primary number uses the treatment-regimen estimand, which counts participants regardless of whether they stopped treatment or used other anti-obesity therapies. People with type 2 diabetes also lose less weight on these drugs: semaglutide 2.4 mg produced -9.6% in STEP 2 (type 2 diabetes) versus -14.9% in STEP 1 (no diabetes).
What the Data Shows
Key Takeaways
- SYNCHRONIZE-2 (n=752) met both primary endpoints: mean weight change at week 76 was -8.2% (3.6 mg) and -9.8% (6.0 mg) vs -3.9% on placebo (treatment-regimen estimand), and 57.6%, 64.5% and 35.1% lost at least 5% of body weight (P<0.001 for both doses vs placebo).
- HbA1c fell from a baseline of 7.4% by 0.9 percentage points (3.6 mg) and 0.8 points (6.0 mg) vs 0.2 on placebo. The higher dose produced more weight loss but not a larger HbA1c drop.
- Gastrointestinal adverse events were the most common, reported in 72.8% (3.6 mg) and 77.7% (6.0 mg) vs 38.6% on placebo, and were generally mild to moderate and transient.
- Weight loss was smaller than in SYNCHRONIZE-1, the sister trial in adults without diabetes, which reported -12.2% (3.6 mg) and -13.0% (6.0 mg) vs -5.4% on placebo at week 76.
- The same gap appears with semaglutide 2.4 mg: -9.6% at week 68 in people with type 2 diabetes (STEP 2) vs -14.9% in people without diabetes (STEP 1).
- In an earlier 16-week phase 2 trial in 413 people with type 2 diabetes on metformin, survodutide lowered HbA1c by up to 1.71 percentage points and body weight by up to 8.7%; weekly doses of 1.8 mg or more cut more weight than open-label semaglutide 1.0 mg (-5.3%).
- How survodutide compares with tirzepatide or semaglutide in type 2 diabetes: SYNCHRONIZE-2 had no active comparator, and cross-trial numbers (SURMOUNT-2: -12.8% and -14.7% at 72 weeks) come from different designs, durations and baseline HbA1c (8.02% in SURMOUNT-2 vs 7.4% here).
- Why 6.0 mg did not lower HbA1c more than 3.6 mg: the published abstract reports the numbers but not an explanation.
- Whether survodutide reduces heart attacks, strokes or diabetes complications: SYNCHRONIZE-2 measured weight and glycemia, not clinical outcomes. The SYNCHRONIZE cardiovascular outcomes trial has a published design paper but no published results.
- What happens to weight and HbA1c after 76 weeks or after stopping treatment.
- Body-composition effects in type 2 diabetes: the MRI body-composition and liver-fat substudy was part of SYNCHRONIZE-1, not SYNCHRONIZE-2.
- When or whether survodutide will be approved: it is investigational and not FDA- or EMA-approved.
Frequently Asked Questions
What is the SYNCHRONIZE-2 trial?
SYNCHRONIZE-2 is a multinational, double-blind phase 3 trial of once-weekly survodutide, an investigational glucagon receptor-GLP-1 receptor dual agonist from Boehringer Ingelheim. It enrolled 752 adults with type 2 diabetes and a BMI of 27 or more, randomized to 3.6 mg, 6.0 mg or placebo for 76 weeks. Results were published in the New England Journal of Medicine in 2026.
How much weight did people lose on survodutide in SYNCHRONIZE-2?
Mean body-weight change at week 76 was -8.2% on 3.6 mg and -9.8% on 6.0 mg, versus -3.9% on placebo, under the treatment-regimen estimand. A weight reduction of at least 5% was reached by 57.6% and 64.5% of participants on the two doses, versus 35.1% on placebo.
Why was weight loss smaller than in SYNCHRONIZE-1?
SYNCHRONIZE-1 enrolled adults with obesity but without diabetes and reported -12.2% and -13.0% at week 76. People with type 2 diabetes typically lose less weight on these drugs; semaglutide 2.4 mg showed the same pattern, with -9.6% in STEP 2 (type 2 diabetes) versus -14.9% in STEP 1 (no diabetes).
Did survodutide lower blood sugar (HbA1c) in SYNCHRONIZE-2?
Yes. From a baseline HbA1c of 7.4%, the mean change was -0.9 percentage points on 3.6 mg and -0.8 points on 6.0 mg, versus -0.2 on placebo. In an earlier 16-week phase 2 trial with a higher baseline HbA1c (about 8.1%), reductions reached up to 1.71 points.
How does survodutide compare with tirzepatide and semaglutide in type 2 diabetes?
There is no head-to-head phase 3 trial. Indirectly, survodutide's -9.8% at 76 weeks sits close to semaglutide 2.4 mg in STEP 2 (-9.6% at 68 weeks) and below tirzepatide in SURMOUNT-2 (-12.8% to -14.7% at 72 weeks). The trials differ in design, duration and baseline HbA1c, so these comparisons are approximate.
Is survodutide FDA-approved or available?
No. Survodutide is an investigational drug in phase 3 development by Boehringer Ingelheim, which funded the SYNCHRONIZE trials. It is not approved by the FDA or EMA.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Peer-Reviewed References
Educational purposes only. Not medical advice.
Survodutide is an investigational drug and is not approved by the FDA or EMA. Figures quoted are group means from published trials; individual results vary.
Talk to your clinician before starting, stopping or changing any diabetes or weight-loss medication.